ALP Bio ^Company

ALP Bio develops a biotechnology platform that helps evaluate and reduce the immunogenicity risk of therapeutic antibodies during the early stages of drug development. The company combines human tonsil organoid technology with artificial intelligence models to assess anti-drug antibody (ADA) risk, validate immune responses using human-derived ex vivo assays, and support the redesign of antibody sequences with lower immunogenic potential. Its platform integrates computational analysis with laboratory testing to provide insights that inform antibody candidate selection and optimization before clinical development. ALP Bio works with pharmaceutical and biotechnology organizations developing antibody-based therapies to improve the prediction and characterization of immune responses.